Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics
Open Access
- 9 May 2007
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 137 (6) , 530-536
Abstract
Summary: Prognostic models for multiple myeloma have been fraught with tremendous heterogeneity in outcome among subgroups. In the context of Total Therapy 2, a tandem transplant trial for newly diagnosed myeloma, comprehensive information was available in 220 patients on standard prognostic factors (SPF), magnetic resonance imaging (MRI)‐defined focal lesions, cytogenetic abnormalities (CA), fluorescence‐in‐situ‐hybridisation (FISH)‐derived amplification of chromosome 1q21 (amp1q21) and deletion of 13q14, as well as gene expression profiling (GEP). Five multivariate analysis‐based survival models were derived, utilising SPF only (model 1), with progressive addition of CA (model 2), MRI (model 3), FISH (model 4) and GEP (model 5). TheR2value, a measure of accounting for clinical outcome variability, increased progressively from 18% in model 1 to 38% in model 5. The hazard ratio for overall survival was highest for GEP (3·07,P < 0·001) followed by amp1q21 (1·71,P = 0·05). According to the presence of none (49%), one (35%) or both of these two risk features (16%), 3‐year survival decreased progressively from 92% to 78% to 43% (P < 0·0001). Thus, the dominance over other prognostic parameters of molecular genetics justifies the generation of quantitative reverse transcription polymerase chain reaction methodology (‘MM genetic kit’) for the optimal risk stratification of patients participating in therapeutic trials.Keywords
This publication has 20 references indexed in Scilit:
- Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical ImplicationsJournal of Clinical Oncology, 2007
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Blood, 2006
- Long‐term outcome results of the first tandem autotransplant trial for multiple myelomaBritish Journal of Haematology, 2006
- The molecular classification of multiple myelomaBlood, 2006
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantationBlood, 2006
- Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapiesBlood, 2006
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Individual Comparisons by Ranking MethodsBiometrics Bulletin, 1945